Demand for combination therapies for the treatment of respiratorydiseases on an increasing spree
May 9, 2019DUBLIN–(BUSINESS WIRE)–The “Global
Asthma & COPD Therapeutics Market, Bronchodilator Monotherapy Market
Outlook 2025” report has been added to ResearchAndMarkets.com’s
offering.
Demand for combination therapies for the treatment of respiratory
diseases has been on an increasing spree. COPD medications such as
long-acting beta-2 agonists (LABAs) and long-acting muscarinic
antagonists (LAMAs) combination in the inhaler is one of the latest
therapeutics being used for the treatment of Asthma and COPD.
The report provides in-depth analysis of the current scenario, detailed
market outlook of the global Asthma & COPD therapeutics market overall
as well as across various geographies. Geographical analysis is done
across major markets such as the US, Japan, China, Germany & France.
The report provides comprehensive coverage on major industry drivers,
restraints, and their impact on market growth during the forecast
period. Furthermore, the study encompasses various market-specific
growth opportunities in global Asthma & COPD therapeutics market.
Key Vendors
-
- AstraZeneca plc
- GlaxoSmithKline plc
- F. Hoffmann-La Roche AG
- Novartis AG
- Merck & Co. Inc.
Topics Covered
1. Executive Summary
2. Research Methodology
3. Respiratory Diseases
3.1 Background
3.2 Types
3.3 Asthma
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Disease
4.2.2 Market Share by Segments
4.2.3 Market Share by Therapeutic Classes
4.2.4 Market Share by Nations
5. Treatment
5.1 Anti-inflammatory Drugs
5.1.1 Inhaled Corticosteroids (ICS)
5.2 Bronchodilator Monotherapy
5.2.1 Long-Acting Beta Agonists (LABA)
5.2.2 Short-Acting Beta Agonists (SABA)
5.3 Others
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
6. Country Analysis
6.1 The US
6.2 Germany
6.3 France
6.4 Japan
6.5 China
7. Market Dynamics
7.1 Industry Trends & Development
7.1.1 Connected Health Solutions
7.1.2 Higher Demand for Combination Therapies
7.1.3 Advent of Stem Cell Therapy
7.2 Growth Drivers
7.2.1 Prevalence of Respiratory Diseases
7.2.2 Environmental Pollution
7.2.3 Government Impetus
7.2.4 Rise in Number of Smokers
7.2.5 Growing Geriatric Population
7.3 Challenges
7.3.1 Stringent Regulatory Compliance
7.3.2 Patent Expiration of Drugs
7.3.3 Side-Effects of Drugs
8. Competitive Landscape
8.1 Drugs Clinical Pipeline
8.2 Financial Analysis
8.3 Market Share Analysis
9. Company Profiles
9.1 AstraZeneca plc
9.2 GlaxoSmithKline plc
9.3 F. Hoffmann-La Roche AG
9.4 Novartis AG
9.5 Merck & Co. Inc.
For more information about this report visit https://www.researchandmarkets.com/r/dzzlx
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs, Inhalers
and Nebulisers, Asthma
Drugs
